PANACRO (Hangzhou) Pharmaceutical Consulting Co., Ltd.

博纳西亚(杭州)医药科技股份有限公司

Hangzhou-based clinical CRO providing clinical trial technical services on a contract basis to pharmaceutical and biotechnology companies in China and internationally, supported by proprietary digital systems such as CTMS, eTMF and CTFS. Ranked 14th in China-headquartered clinical CRO revenue in 2025 with 0.7% market share (per the prospectus).

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Business changes and acquisitions
• Key long-term agreements
• Backlog and project economics
• Decline in revenue or profit
• Working capital: receivables, prepayments and cash cycle
• Preferred shares and fair-value liabilities
• Non-IFRS measures and adjustments
• Related-party transactions and balances